Under its agreement with Recordati to reacquire the UK rights to its once-daily tramadol product, Labopharm will continue to use the brand name Tradorec XL in marketing its product. Labopharm will also receive E700,000 milestone from Recordati upon termination of Recordati’s rights.
To promote its product in the UK, Labopharm will engage a contract sales organization and pursue a new licensing and distribution agreement with an appropriate marketing partner. Labopharm is in discussions to finalize an agreement with a contract sales organization to promote Tradorec XL in the UK.